Bluebird’s Zynteglo safety snag could spell trouble for other gene therapies: analysts

Cancer cases that cropped up in a clinical trial definitely set back Bluebird Bio’s one-time blood disorder gene therapy Zynteglo. But the incident could ripple beyond the company's specific products, analysts argued.